AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Amarin Corporation plc

2 Pembroke House
Upper Pembroke Street 28-32
Dublin 2
Ireland
353 1 669 9020
http://www.amarincorp.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees215

Key Executives

NameTitlePayExercisedAge
Mr. John F. TheroChief Exec. Officer, Pres and Director1.11MN/A56
Mr. Michael W. Kalb CPAChief Financial Officer and Sr. VP293.2kN/A46
Dr. Steven B. Ketchum Ph.D.Chief Scientific Officer, Pres of R&D and Sr. VP631.56kN/A52
Mr. Joseph T. Kennedy J.D.Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec.672.54kN/A49
Mr. Frederick W. Ahlholm CPAChief Accounting Officer and VP of Fin. & Admin.N/AN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Corporate Governance

Amarin Corporation plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.